Sonoma Pharmaceuticals (SNOA) Net Cash Flow (QoQ) (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,840.99% |
| Mar 31, 2026 | 73.21% |
| Dec 31, 2025 | 14.99% |
| Sep 30, 2025 | 67.55% |
| Jun 30, 2025 | -2,279.00% |
| Mar 31, 2025 | -92.13% |
| Dec 31, 2024 | -28.27% |
| Sep 30, 2024 | 730.60% |
| Jun 30, 2024 | -135.48% |
| Mar 31, 2024 | 271.83% |
| Dec 31, 2023 | 115.64% |
| Sep 30, 2023 | -271.12% |
| Jun 30, 2023 | -143.23% |
| Mar 31, 2023 | 234.34% |
| Dec 31, 2022 | 71.21% |
| Sep 30, 2022 | -12.97% |
| Jun 30, 2022 | -57.46% |
| Mar 31, 2022 | -1,000.73% |
| Dec 31, 2021 | -97.57% |
| Sep 30, 2021 | 479.95% |